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Abstract (300 words max) 
Rhomboid proteases form the most widespread family of intramembrane proteases. They utilize a 
catalytic serine-histidine dyad located several Å below the surface of the membrane for substrate 
hydrolysis. Multiple studies have implicated rhomboid proteases in biologically and medically relevant 
processes. Several assays have been developed that are able to monitor rhomboid activity. With the aid of 
these assays, different types of inhibitors have been found, all based on electrophiles that covalently react 
with the active site machinery. Although the currently available inhibitors have limited selectivity and 
moderate potency, they can function as research tools and as starting point for the development of 
activity-based probes, which are reagents that can specifically detect active rhomboid species. Structural 
studies on complexes of inhibitors with the E. coli rhomboid GlpG have provided insight into how 
substrate recognition may occur. Future synthetic efforts, aided by high-throughput screening or structure-
based design, may lead to more potent and selective inhibitors for this interesting family of proteases. 
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Highlights 
 Rhomboid proteases are the most widespread intramembrane proteases 
 Several different assays have been developed to monitor rhomboid protease activity 
 Current inhibitor classes include different types of electrophiles 
 Current inhibitors have limited potency and selectivity 
 Crystal structures of rhomboid-inhibitor complexes provide mechanistic insights 
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Abbreviations 
ABP: activity-based probe, BODIPY: boron-dipyrromethylene, DCI: 3,4-dichloro-isocoumarin, DFP: 
diisopropyl-fluorophosphate, DmRho1: Drosophila melanogaster rhomboid-1, FITC: fluorescein 
isothiocyanate, IMP: intramembrane protease, MALDI-TOF: matrix-assisted laser desorption ionization 
time-of-flight, S2P: site-2 protease, SPP: signal peptide peptidase, TGF: transforming growth factor 
alpha, TM: transmembrane helix. 
 
  
1. Introduction 
In 1997, site-2 protease was discovered as a first intramembrane protease (IMP) [1]. Although proteolysis 
within the membrane seems a counterintuitive process, the following years brought several other reports 
about IMPs. As our understanding of intramembrane proteolysis grows each year, IMPs have now turned 
from surprising exceptions to recognized members of the protease family [2-6]. 
   From the primary amino acid sequence it is apparent that IMPs have an entirely different architecture 
compared with soluble proteases. However, their active sites resemble those of soluble proteases – a 
typical example of convergent evolution. IMPs contain multiple transmembrane helices (TMs) and reside 
within the lipid bilayer of a membrane. Their active sites are buried several Å below the surface of the 
membrane boundary and are formed by residues in different TMs (Fig. 1). The native substrates of IMPs 
are also transmembrane proteins and are cleaved within a TM or a juxtamembrane region. Through this 
cleavage, a soluble part of the substrate is released from the membrane to the exterior or interior of the 
cell or organelle, and can function in downstream pathways, in a role distinct from the full-length 
progenitor form [2-5]. IMPs can be classified into four groups: (1) Aspartyl IMPs, also GXGD proteases, 
named after part of their active site motif. Examples include the signal peptide peptidase family (SPP) [7] 
and -secretase [8, 9]; (2) glutamate IMPs, which include the recently discovered Rce1 [10]; (3) metallo 
IMPs, exemplified by the site-2 protease family (S2P) [1]; and (3) serine IMPs, also known as rhomboid 
proteases [11]. 
   Rhomboids were first discovered in Drosophila melanogaster. In this organism, Rhomboid-1 cleaves 
the transforming growth factor α (TGF) homolog Spitz, an important player in the epidermal growth 
factor receptor pathway [11, 12]. Aided by bioinformatics, it became clear that rhomboids occur in almost 
all organisms and are present in all phylogenetic domains of life: archaea, bacteria and eukaryota [13, 14]. 
A variety of studies have now indicated a functional role for rhomboids, for example in bacterial 
communication (quorum sensing) [15], cleavage of adhesins that apicomplexan parasites use to invade 
host cells [16-19], mitochondrial membrane dynamics [20-23], and cleavage of Pink-1, a protein involved 
in Parkinson’s disease [24, 25]. 
   In the past, the development of small molecule inhibitors and activity-based probes (ABPs) has been 
crucial for the study of soluble proteases. An advantage over genetic knock-outs is that small molecules 
can be introduced at a specific time and place. In addition, in the case of ABPs, the targeted proteases can 
be subsequently analyzed by biochemical methods. Because of their roles in biomedically relevant 
processes, rhomboid proteases could become future drug targets, but whether rhomboids are druggable, 
has not yet been validated. The development of selective inhibitors and other chemical tools for functional 
characterization of rhomboids will be crucial in order to answer this question. 
   In this review article we will give an overview of the major milestones in rhomboid inhibitor research. 
We will first discuss the available activity assays that enable monitoring of rhomboid protease activity. 
Next, we will present the available inhibitors and discuss their respective merits. We will provide a brief 
overview of the available ABPs for the study of rhomboids. Finally, we will discuss crystal structures of 
rhomboids in complex with their inhibitors. 
 
 
Fig. 1. The Escherichia coli rhomboid GlpG was the first IMP that was structurally characterized by X-
ray crystallography. Its structure is formed by six TMs, connected by several loops. The larger loop L1 is 
partially immersed within the membrane. Loop L5 sits as a ‘cap’ on top of the active site. S201 in TM4 
and H254 in TM6 (both in stick representation) form the catalytic center, which is buried within the plane 
of the membrane. 
 
2. Activity assays 
An assay to detect rhomboid protease activity is a prerequisite for measuring inhibition of rhomboids.  
Several types of activity assays have been developed. Initially, these aimed to prove that rhomboids 
indeed act as proteases and hydrolyze membrane proteins. Later, assays were adapted or developed in 
order to screen for inhibition. In the next sections, we have grouped the assays according to the type of 
molecules that are used as a read-out for activity: membrane proteins, soluble polypeptides or proteins 
that incorporate fluorophores, and activity-based probes (Fig. 2). 
 
2.1 Membrane proteins 
The very first proof that rhomboids are a class of intramembrane proteases came from cell biology studies 
on Drosophila melanogaster Rhomboid-1 (DmRho1) [11]. DmRho1 was known to play a role in EGF 
signaling, but the mechanism was unclear. Transient expression of DmRho-1, the TGF- homolog Spitz 
and its chaperone Star in eukaryotic cell culture showed that DmRho-1 cleaves Spitz within its TM, 
thereby setting it free from the membrane [11]. The proteolytic processing was confirmed by Western blot 
detection of the GFP-tagged substrate Spitz in the supernatant of the cells. 
   In general, proteolytic processing leads to a reduction in size and therefore a shift in retention in 
acrylamide gels (Fig. 2A). This principle has been used in various other studies using recombinant 
rhomboid substrates that incorporate various tags such as His6 or GFP. The assay is easy to perform and 
flexible, as it can be carried out in different settings: it has been used in living E. coli cells with Western 
blot detection [26, 27], on purified rhomboids in micelles or liposomes with either Western blot detection 
[28-30], Coomassie staining [31], autoradiography using an in vitro translated S35-labeled substrate [32-
34], or direct gel scanning using a fluorescently-labeled substrate [35]. This fluorescently-labeled 
substrate was based on a recombinant form of TatA (a native substrate of Providencia stuartii rhomboid 
AarA) that had been modified with a fluorophore using a Sortase A labeling strategy [36]. The same TatA 
protein was modified with derivatives from cyan and yellow fluorescent protein on the N- and C-terminal 
side, respectively, yielding a recombinant FRET membrane protein substrate. It was subsequently used in 
real-time kinetics measurements of different bacterial rhomboid species  [30]. 
   A reduction in the size of a substrate protein can also be measured by mass spectrometry. Vosyka et al. 
developed a MALDI-TOF-based assay to monitor cleavage of a recombinantly expressed and purified 
rhomboid substrate by E. coli GlpG and P. stuartii AarA [37]. This method was used to screen a small 
selection of compounds in order to find new rhomboid inhibitors. The benefit of the assay was the parallel 
measurement of up to 384 samples on a single MALDI-TOF plate and the automatic detection of the 
substrate and product peak intensities, from which the percentage of activity in comparison to a control 
was calculated [37]. 
 
 
Fig. 2. Different methods to detect rhomboid protease activity. A) The cleavage of a transmembrane 
protein substrate within its TM results in protein fragments with a lower mass than the parent structure. 
The fragments can be analyzed by mass spectrometry or gel-based techniques. B) Surprisingly, soluble 
proteins or polypeptides can also be cleaved by rhomboid proteases. When decorated with multiple 
fluorophores or a fluorophore-quencher pair, this results in a fluorescently quenched reporter. Cleavage 
causes a gradual increase in fluorescence, which can be spectrophotometrically measured over time. C) 
Activity-based probes consist of a reactive group (triangle), a spacer (line) and a tag (star). Several ABPs 
have been reported for rhomboid proteases. They react with active rhomboid proteases and facilitate 
detection by gel-based or fluorescence techniques. 
 
2.2 Soluble fluorescent proteins or peptides 
Fluorescently-labeled casein (e.g. FITC-casein [38] or BODIPY-casein [39]) is a commercially available 
protein that has been used as a general substrate for a variety of proteases. Because multiple fluorophores 
are incorporated on the same protein molecule, the fluorescence is quenched (Fig. 2B). Therefore, these 
proteins cannot only be used in a gel-based read-out but also for spectrophotometric detection in real 
time. 
   The group of Akiyama showed that BODIPY-labeled casein can also be cleaved by rhomboid (GlpG) 
and its processing monitored in time by measurement of fluorescent intensity [26]. At the moment, it is 
not known at which sites casein is cut and how this proteolytic processing takes place, but it is likely that 
the soluble substrate approaches the catalytic machinery from the ‘top’ side when the L5 ‘cap’ that covers 
the active site (Fig. 1) lifts upwards. The same substrate was used by the group of Ha to show that 
removal of the cytoplasmic domain of GlpG reduces the cleavage rate [40]. In a later study, BODIPY-
labeled casein was applied in order to demonstrate that GlpG does not form a stable complex with the 
inhibitor DCI, but slowly regains activity over time [41]. The group of Lemieux applied BODIPY-casein 
in kinetic studies of rhomboid proteases. It was found that the cytoplasmic domain of GlpG does not have 
a profound effect on the catalytic parameters kcat and KM [42]. Furthermore – aided by experiments with a 
membrane protein substrate – it was found that some bacterial rhomboids are allosterically regulated and 
contain an exosite that is formed upon dimerization [30]. 
   The Freeman laboratory designed a synthetic 15-mer polypeptide, based on the sequence around the 
scissile bond of Gurken, a D. melanogaster TGF homolog that is cleaved by rhomboids from several 
species. The peptide was decorated with a fluorophore on one end of the cleavage site and a fluorescence 
quencher on the other end [43]. This resulted in a fluorogenic substrate suitable for high throughput 
screening. A different type of ‘quenched’ substrate was discovered by the Urban laboratory.  The 
substrate, based on the first 33 amino acids of TatA, was chemically synthesized with an N-terminal 
FITC. Surprisingly, when this peptide was incorporated into liposomes, the FITC fluorescence was 
quenched, and cleavage by GlpG resulted in an increase of fluorescence over time [44]. The substrate was 
applied in the study of rhomboid kinetics in a membrane environment. 
 
2.3 Activity-based probes 
ABPs (Fig. 2C) are often derived from covalent electrophilic inhibitors and incorporate a detection tag 
such as a biotin or a fluorophore. Since they only react with the active enzyme species, they can be 
utilized as a read-out of an enzyme’s activity state. For rhomboids, several activity-based probes have 
been reported [35, 37, 45]. They enable a variety of different detection methods including gel-based 
analysis [35, 37, 45], fluorescent polarization in 96-well plate format [35], and fluorescent microscopy 
[46]. The structures and applications of rhomboid ABP will be discussed in more detail in section 4. 
 
3. Inhibitors 
The discovery of rhomboid proteases in 2001 also marks the start of the search for rhomboid protease 
inhibitors. All currently known inhibitor classes are listed with numbers in Fig. 3. Experiments with 
DmRho-1 suggested that rhomboids are insensitive to most broad-spectrum serine protease inhibitors. 
Only high concentrations of 3,4-dichloroisocoumarin (DCI; 1 Fig. 3A) and N-tosyl-phenylalanine-
chloromethyl ketone (TPCK; 9) were able to block processing of the model substrate Spitz by DmRho-1 
in cell culture experiments [11]. Inhibitors with other structures have also been reported – most of them 
for GlpG. They include isocoumarin analogs, fluorophosphonates, β-lactams, β-lactones and peptidyl 
chloromethyl ketones. All of these inhibitors display a covalent inhibition mechanism (Fig. 3): they 
consist of electrophiles that react with the active site serine and in some cases with an additional residue. 
In the next sections, we will discuss all currently known classes of rhomboid inhibitors. IC50 values of 
covalent inhibitors heavily depend on the time that the enzyme is preincubated before a read-out of 
activity is performed. It is therefore hard to compare the inhibitor potency from different studies. Where 
we mention potency, we therefore also indicate the preincubation time. 
 
3.1 Isocoumarin analogs 
As mentioned above, DCI was found as the first rhomboid inhibitor, blocking the activity of DmRho1 
[11]. In later studies, DCI was found to inhibit rhomboids from a wide range of organisms: P. stuartii 
AarA [28], B. subtilis YqgP [28, 32], E. coli GlpG [41], the rhomboid from A. aeolicus [28], T. gondii 
ROM5 [18], H. sapiens PARL [47, 48] and RHBDL2 [49]. DCI is therefore considered a pan-rhomboid 
inhibitor. We must stress, however, that DCI is not selective for rhomboids, but inhibits a wide range of 
serine proteases, and that the potency of DCI varies considerably between rhomboids (Wolf & Verhelst, 
unpublished observations). 
   In a series of experiments that aimed at making crystals of GlpG in complex with DCI, it was found that 
the covalent bond between the active site serine and the carbonyl group of DCI is not stable [41]. It is 
therefore not surprising that a crystal structure could not be obtained. GlpG turns over the DCI by slowly 
hydrolyzing the ester bond (Fig. 3A). Over the course of several days, it thereby regains its activity [41]. 
This is consistent with results obtained for soluble serine proteases [50]. 
   JLK-6 (2), an isocoumarin analog with a 7-amino-group, was also found to inhibit GlpG [51]. Due to 
the presence of a 7-amino group, the reaction mechanism is different from DCI (Fig. 3B). After attack of 
the active site serine onto the isocoumarin carbonyl group, the scaffold opens and forms a secondary 
electrophile, which subsequently reacts with the active site histidine H254. This mechanism is known 
from soluble serine proteases, such as porcine pancreatic elastase [52]. For GlpG, the formation of a 
double-bonded enzyme-inhibitor complex was confirmed by X-ray crystallography [51] as well as by a 
gel-shift assay [37]. The gel-shift can be explained by a lower apparent molecular weight of the more 
compact crosslinked species. The ester bond formed between the serine and the carbonyl group of the 
isocoumarin slowly hydrolyzes over time, just like for DCI [37]. However, GlpG remains inactive due to 
the irreversible alkylation of the histidine residue. 
   The isocoumarin derivative S016 (3) was found to be one order of magnitude more potent than DCI 
(IC50 of 0.7 M versus 6 M; 30 min preincubation time) [37]. Interestingly, a different binding mode 
was observed for derivative S016 compared to JLK-6. Instead of reaction with active site histidine H254, 
it forms a covalent bond with H150, which is part of the oxyanion hole (see also paragraph 5). 
 
3.2 -lactams and -lactones 
In a high-throughput screen of almost 60,000 compounds against the rhomboid AarA, N-sulfonylated -
lactams (4) were identified as rhomboid inhibitors (Fig. 3C) [43]. The N-sulfonyl group can be replaced 
by a carbamate group (5) [43, 53]; both are electron withdrawing groups that activate the lactam 
electrophile. Upon reaction with the active site serine, the lactam ring opens, which was corroborated by 
X-ray crystallography (see paragraph 5) [53]. Most -lactams that showed activity against AarA, were 
more potent against GlpG. The most potent compound displayed an IC50 value of 0.4 M against GlpG 
(30 min preincubation). A small number of -lactams were also capable of inhibiting mouse rhomboid-2 
[43]. 
   Wolf et al. reported -lactones (6) as modest inhibitors of GlpG (IC50 of 26-44 M with 30 min 
preincubation) [35]. -lactones have a similar central scaffold as -lactams and also open the four-
membered ring upon reaction with the active site serine (Fig. 3C). The reported compounds contained a 
terminal alkyne functionality, which is amenable to functionalization by click chemistry (see paragraph 
4). The covalent mechanism of these compounds could therefore be shown on gel after functionalization 
of the covalent enzyme-inhibitor complex with a fluorescent dye [35]. 
 
 
Fig. 3. Structures and mechanisms of all currently known classes of rhomboid protease inhibitors. A) DCI 
reacts with the active site serine of rhomboids, yielding an ester intermediate that slowly hydrolyzes. B) 
4-chloro-isocoumarins such as JLK-6 and S016 carry a substituent at the 7-position of the isocoumarin 
scaffold. This results in the formation of a quinone imine methide electrophile, which can react with a 
histidine residue in the active site, forming a stable covalent enzyme-inhibitor complex. C) -lactams and 
-lactones react with the active site serine, opening the 4-membered ring structure. D) Fluorophosphate 
DFP or fluorophosphonate CAPF react at the electrophilic phosphoryl atom with the fluoride acting as a 
leaving group; iPr = isopropyl. E) Chloromethyl ketones first form a reversible hemi-ketal with the active 
site serine, analogous to a tetrahedral intermediate. Next, the active site histidine is alkylated by attack 
onto the chloromethylene group. 
 
3.3 Others 
In 2012, the Ha laboratory showed that the general serine hydrolase inhibitor DFP (7) completely and 
irreversibly inhibits GlpG at concentrations 80 M by reaction with the active site serine. The more 
peptide-like fluorophoshonate CAPF (8), mimicking an alanine residue, also leads to a covalent adduct 
with the S201 of GlpG (Fig. 3D) [41]. The application in lysates or cells may be limited, since peptidyl 
fluorophosphonates are unstable in aqueous solution and rapidly hydrolyze [54]. 
   The early observation that TPCK (9) is a weak inhibitor of DmRho-1, urged Zoll et al. to synthesize a 
number of peptidyl chloromethyl ketone analogs that have a longer peptide chain with residues that are 
based on the substrate specificity of GlpG in the P4-P1 position (10) [34]. These compounds react with 
GlpG by forming a hemi-ketal with the active site serine followed by alkylation of the active site histidine 
(Fig. 3E), as confirmed by X-ray crystallography (see paragraph 5). Although the resulting compounds 
were not very potent (IC50 value of approximately 100 M, 180 min preincubation), they represent the 
first peptidic inhibitors that likely form similar interactions with the protease as a substrate. 
 
4. Activity-based probes 
ABPs are small molecule tools that can probe the activity of enzymes. Generally, they consist of a 
reactive group, a spacer, and a reporter tag. The reactive group often consists of an electrophilic trap that 
covalently binds to an active site residue in a mechanism-based reaction. The electrophilic trap is 
commonly derived from covalent enzyme inhibitors. The spacer may contain binding motifs for the 
enzyme that influence the selectivity of the ABP. The reporter tag, such as a biotin or a fluorophore, can 
be used for purification or detection of the probe-bound target. Efforts in synthetic chemistry have 
allowed to fine-tune the selectivity of ABPs, resulting in broad-spectrum probes for tagging an entire 
family of enzymes or highly selective probes that target only one single enzyme [55]. ABPs have been 
especially useful in protease research [56, 57]. 
   In the past, fluorophosphonates (Fig. 4A) have been used as broad-spectrum ABPs for serine hydrolases 
[58, 59]. They are based on the broad spectrum serine protease and esterase inhibitor DFP. Although DFP 
only acts as a weak rhomboid protease inhibitor, the fluorophosphonate ABPs react with the active site 
serine of GlpG at concentrations as low as 10 nM [45]. More importantly, these ABPs react with 
rhomboid proteases from a wide variety of organisms (Wolf & Verhelst, unpublished observation). 
   Sherratt et al. used the fluorescently labeled fluorophosphonate ABP FP-PEG-Rh (Fig. 4A) to identify 
residues in GlpG that are directly involved in the formation of an intact catalytic site [45]. Wolf et al. 
developed an inhibitor screening method for GlpG based on fluorescent polarization with a FP-Rh [35], a 
technique originally developed as a high-throughput screening method for poorly characterized soluble 
enzymes without the necessity of having a substrate [60]. This method is based on the large difference in 
molecular size of an unbound and an enzyme-bound ABP, resulting in a large difference in the tumbling 
rate. When the fluorophore is excited with polarized light, an unbound ABP will emit depolarized light, 
whereas the fluorescence of a bound ABP will remain polarized (Fig. 4B). It turned out to be crucial to 
have a suitable detergent that does not interfere with fluorescence polarization and also solubilizes 
rhomboid in an active form. Using this assay, -lactones were found as novel rhomboid inhibitors [35]. 
The -lactones inhibitors carried alkyne groups amenable to the introduction of a detection tag by click 
chemistry, which classifies these compounds as ABPs as well (Fig 4C). Vosyka et al. reported ABPs 
based on the isocoumarin inhibitor scaffold, all containing alkyne groups [37]. Experiments in this study 
demonstrated that these compounds can be used either in a two-step click chemistry labeling approach or 
directly as pre-clicked probes that already contain a fluorophore (Fig. 4D). Gel-based analysis also 
showed that the ester bond formed between the carbonyl group of the isocoumarin and the side chain of 
the active site serine residue is labile and hydrolyzes over time, but that alkylation of the histidine leads to 
a stable complex (Fig. 3B). 
   Recently, ABPs were also applied in the labeling of rhomboid proteases in liposomes [46]. In contrast 
to detergent micelles, liposomes embed rhomboids within a lipid bilayer. However, this study showed that 
the identification of inhibitors is not affected by the environment, confirming that micelle-solubilized 
rhomboids are a suitable model system. Furthermore, it was shown that fluorescent ABPs can be used to 
visualize rhomboids in giant unilamellar vesicles by fluorescence microscopy [46]. 
 
 
Fig. 4. Activity-based probes for rhomboid proteases. A) The fluorophosphonates FP-PEG-Rh and FP-
Rh, containing a tetramethylrhodamine fluorophore, can both be utilized as rhomboid protease ABPs. 
Analogous to DFP, they react with the active site serine residue. B) Schematic representation of 
fluorescent polarization activity-based protein profiling for rhomboid proteases. A rhomboid-ABP 
complex has a low tumbling rate, which does not result in a loss of polarization of the emitted 
fluorescence. An inhibited rhomboid cannot react with the ABP. The unbound ABP has a high tumbling 
rate, which will result in depolarized fluorescence. C) -lactone inhibitors with a terminal alkyne group 
can function as ABPs. The covalent complex of the rhomboid and the inhibitor can be decorated with a 
fluorophore or another detection tag by click chemistry. D) Alkyne-containing isocoumarins have also 
been applied as ABPs. They can either be used as is and tagged at level of the inhibitor-rhomboid 
complex or they can be pre-clicked with a fluorophore and used without requirement for further 
functionalization at the protein level. 
 
5. Inhibitor-rhomboid structures 
In 2007, Ha and co-workers reported the crystal structure of the E. coli rhomboid GlpG, which was the 
first structure of an intramembrane protease [40]. It was quickly followed by several other structures, of 
GlpG from E. coli [61, 62] and H. influenzae [63]. These structures showed that the rhomboid consists of 
six alpha-helical TMs creating a cup-like structure containing an active site Ser-His dyad for catalysis, 
which is located approximately 10 Å below the membrane surface (Fig. 1). Several water molecules were 
found within the protein cavity, explaining how hydrolysis can take place within the membrane. The 
active site serine, located on top of the shorter TM4 helix, is surrounded by the other TMs, and in several 
structures, the active site is closed by a cap formed by loop 5 (L5). This implies that the substrate can only 
approach the active site machinery upon rearrangement of the rhomboid structure. The reported crystal 
structures led to several hypotheses about the mechanism: either through a lateral gate between TM2 and 
TM5 after movement of TM5 or by bending into the active site after lifting of cap L5 (Fig. 5A). The 
lateral gate model is supported by mutational analysis of the TM2/TM5 interface [27, 64]. However, a 
different study showed that chemical crosslinking of TM2 and TM5 did not have a significant effect on 
proteolysis [31]. Some recent studies, however, suggest again that widening of the space between TM2 
and TM5 is possible and leads to a cleavage of the model substrate Spitz at a site that is located deeper 
into the membrane [29, 66]. 
   All in all, it still remains elusive how substrates interact with rhomboids, since no co-crystal structure of 
a rhomboid with a substrate has been reported. Complexes of the E. coli rhomboid GlpG with different 
inhibitors, however, have provided insights into how substrates might be recognized. The first of these 
structures was solved by Vinothkumar et al. [51] and contains JLK-6 (2). From crystallographic studies of 
soluble serine proteases it was known that 4-chloro-isocoumarins with a 7-amino function may not only 
react with the active site serine, but also with a second nucleophile in the active site [52]. The GlpG JLK-
6 structure indeed showed an opened isocoumarin ring structure and binding to both catalytic residues, 
S201 and H254 (Fig. 5B). The carbonyl group is within hydrogen bonding distance of several residues 
including H150 and N154, part of the oxyanion hole. Furthermore, the 7-aminogroup occupies a space 
which is believed to be the S1 pocket. 
   Structures with several other inhibitors have also been elucidated: with DFP (7) [41], the phosphonate 
CAPF (8) [65], the sub-micromolar isocoumarin S016 (3) [37], several N-carbamoylated -lactams (5) 
[53] and a tetrapeptide chloromethyl ketone (10) [34]. The similarities between the structures are striking 
and the several interesting observations can be made. Most structures show interaction of phosphoryl or 
carbonyl oxygen atom with residues in the oxyanion hole (Fig. 5C) [34, 37, 41, 51, 65]. Only in the -
lactam structures, the oxygen points away from these residues [53]. In all inhibitor-rhomboid complexes, 
loop L5 that covers the active site is partially lifted or disordered (Fig. 5D). This indicates that L5 needs 
to move to grant access to the active site. TM5 only shows subtle movement upon inhibitor binding, but it 
must be noted that the inhibitors are small compared to a full substrate, especially at the primed site. 
 
Fig. 5. Structural characterization of E. coli rhomboid GlpG aided by inhibitors. PDB codes are given for 
each structure. A) The L5 cap lifts upwards upon binding of most inhibitors (cyan – 3UBB). Apoenzyme 
is depicted in green (2IC8). One other apoenzyme did not only show lifting of the L5 cap, but also 
movement of TM5 (3NRF). B)  A crystal structure of the isocoumarin JLK-6 with GlpG (2XOW) 
confirms that the inhibitor is bound to two amino acid side chains: S201 and H254. C) The oxyanion hole 
is formed by side chains of H150 and N154 and the backbone amides of L200 and S201. Note that the 
carbonyl of the isocoumarin (2XOW; inhibitor in white), the carbonyl of the peptidyl chloromethyl 
ketone (4QO2; inhibitor in magenta) and the phosphoryl group of CAPF (3UBB; inhibitor in yellow) all 
point towards these residues. D) An overlay of the apoenzyme (green; 2IC8) with three inhibitor-bound 
structures shows that there is virtually no movement in TM5, but that the L5 cap is lifted (yellow: 2XOW, 
magenta: 3UBB) or disordered (white: 3ZMI). E) The more potent isocoumarin S016 (in yellow) showed 
a different binding mode and reacted with H150 (3ZEB). F) Both the phenethyl group on the isocoumarin 
S016 (in yellow) and the Cbz group of CAPF (in pink) protrude between TM2 and TM5, above the 
residues F153 and W236. The GlpG structure bound to S016 is drawn in white, GlpG bound to CAPF is 
depicted in green. G) Plastic formation of the S2’ pocket upon binding of a -lactam inhibitor (3ZMI). 
The apoenzyme (2IC8) is depicted in green, the inhibitor-bound enzyme in white. The inhibitor, 
covalently bound to S201 is colored yellow. Rotation of the side chain of W236 opens a cavity formed by 
the side chains of residues W157, V204, Y205, M208, A233 and I237 (surface representation). 
 
In contrast to the structure with JLK-6, isocoumarin S016 (3) shows a different binding mode: covalent 
binding occurs to S201 and the non-catalytic residue H150 (Fig. 5E). The reactivity of H150 suggests that 
this sidechain might have additional functions besides the stabilization of the oxyanion hole. The 
difference compared with JLK-6 may be explained by the hydrophobic interaction of the phenyl 
substituent that extends between TM2 and TM5 and may ‘pull’ the reactive electrophile away from H254. 
Interestingly, in the structure of CAPF (8) and N-carbamoylated -lactams (5), a hydrophobic substituent 
also protrudes between TM2 and TM5 (Fig. 5F). It suggests that this could be the entry point for a 
substrate peptide chain to enter the active site. This idea is supported by recent molecular dynamics 
calculations [34]. 
   In several of the GlpG-inhibitor structures, it was found that the pockets to accommodate the 
substituents on the inhibitors – and likewise the sidechains of a protein substrate – were plastically 
formed upon the interaction with the ligands. Binding of -lactams, for example, led to rotation of W236 
together with lifting of the L5 cap, opening the S2’ pocket (Fig. 5G) [53]. A crystal structure of a 
tetrapeptide chloromethyl ketone, the most substrate-like structure to date, revealed that the S4 subsite 
adjusts itself depending on the P4 residue, by rearrangements of residues in the L1 loop [34]. 
   At present, it is still ambiguous how a substrate precisely interacts with the rhomboid protease and gains 
access to the active site. The two different models comprise: (1) A lateral gate between TM2 and TM5, 
which controls the reaction kinetics (Fig. 6A, left). Substrates are discriminated from nonsubstrates 
through their intrinsically less stable helices [44]. (2) Access to the active site by a lifted loop L5 (Fig. 
6A, right). Formation of substrate recognition pockets, such as the S2’ pocket, takes place through subtle, 
binding-induced rearrangements (Fig. 6B). The helical substrate part that remains outside of the active 
site may bind to the rhomboid surface at a yet unidentified exosite, as first suggested by the Freeman 
group [33] (Fig. 6A, right). 
   We must emphasize that both models have several features in common. In both cases, a partially 
unwound substrate bends into the active site between TM2 and TM5. This either occurs above the 
residues W236 and F153, as suggested by crystal structures with inhibitors [37, 53, 65] and crosslinking 
studies [31], or the TM2-TM5 interface may be opened wider and grant a deeper access of the substrate 
into the active site [27, 64, 66]. In both models, displacement of the L5 loop facilitates binding of the non-
primed site substrate residues. 
   Upon the binding of the substrate, the scissile bond is able to approach the active site serine, located on 
top of the shorter helix of TM4. The serine oxygen nucleophile, activated by the active site histidine, now 
attacks the scissile bond. The resulting tetrahedral intermediate is stabilized through interactions with 
several residues in the oxyanion hole (Fig. 6B). Collapse of the tetrahedral intermediate gives an acyl-
enzyme and an amine product corresponding to the primed site peptide. In the last steps, the acyl-enzyme 
is hydrolyzed with aid of a water molecule, which may be retained by a specific ‘water retention site’ 
[67]. This ends the catalytic cycle and forms back the active rhomboid species. 
 
 Fig. 6. A) Two models of substrate cleavage. Left: an intrinsically instable helix will unwind and enter the 
rhomboid active site between the lateral TM2/TM5 gate, upon which cleavage occurs. Right: lifting of 
cap L5, and binding to recognition pockets around the active site and possibly an exosite brings the 
substrate in contact with the active site machinery and cleavage takes place. B) Several close-ups of key 
features. Left: The catalytic serine attacks the scissile bond, leading to formation of the tetrahedral 
intermediate, which is stabilized by the oxyanion hole. Middle: amino acid side chains on the substrate 
interact with several binding-incuded pockets, such as the depicted S2’ pocket, formed by movement of 
W236. Right: the acyl enzyme intermediate (only the carbonyl and C are depicted) undergoes hydrolysis 
with the aid of a water molecule, which may originate from a water retention site near the active site. 
Bottom scheme: chemical mechanism of substrate hydrolysis and restoration of the active enzyme. 
 
6. Conclusion and future directions 
Although rhomboid proteases are structurally the best characterized family of IMPs, the development of 
inhibitors is still in its infancy. In this review, we have discussed several aspects of rhomboid inhibitors, 
ranging from the available activity assays, to the reported inhibitors and ABPs, and the usage of inhibitors 
in structural studies. Although multiple substrates to measure rhomboid activity are known, a reporter 
substrate that functions for all rhomboids is still missing. Further knowledge of the substrate specificity of 
rhomboid proteases may yield such a substrate. To date, substrate specificity studies have focused on 
modifications in a few model substrates. The discovery of more native rhomboid substrates would 
therefore be beneficial, also in view of the further elucidation of the biological roles of rhomboids. 
   X-ray crystallography studies on covalent complexes of GlpG with different inhibitors have revealed a 
variety of different structural features, such as the location of the oxyanion hole, the plasticity of the 
pockets to which the inhibitor (and likely the substrate) binds, and the possible entry point of the substrate 
into the active site. However, continued future efforts in organic chemistry, biochemistry and structural 
biology are needed to draw a full picture of the rhomboid-substrate interaction.  
   The potency of most current rhomboid inhibitors is modest. In addition, their selectivity is not well 
studied. For some of these inhibitors, the selectivity is low, e.g. DFP and DCI, which are broad spectrum 
serine protease inhibitors. Also the -lactones have been reported to react with various other targets [68]. 
For the reported -lactams, isocoumarins and tetrapeptide chloromethyl ketones, the selectivity is not well 
defined. Some -lactams showed good selectivity for GlpG over chymotrypsin with ratios of the apparent 
IC50 up to approximately 130 [43]. However, it is unknown whether they may react with other proteases 
or hydrolases. For isocoumarin S016, a more than 60-fold selectivity was found over trypsin, but it 
showed slightly higher activity against chymotrypsin [37]. The selectivity of the GlpG inhibitors based on 
tetrapeptide chloromethyl ketones is not reported, but it is known from previous studies that chloromethyl 
ketone electrophiles can react with both serine and cysteine proteases [54]. 
   In view of the above, a major future challenge in rhomboid research is the development of potent 
inhibitors that display selectivity over other proteases and possibly over rhomboids from other organisms. 
But how can the potency and the selectivity of rhomboid inhibitors be increased? Peptidyl chloromethyl 
ketones are restricted to interaction with the non-primed site. Although the reported peptide scaffold 
already matches an optimal cleavage motif of GlpG [34], the usage of non-natural amino acids, as 
successfully applied for other types of proteases [69], may increase potency and selectivity. Some analogs 
of -lactams and isocoumarins have been synthesized [37, 43], but additional optimization of the 
substituents in both scaffolds might result in higher selectivity. Since crystal structures are reported for all 
of the above mentioned inhibitor classes, a structure-based approach could be taken. However, one 
problem is that the recognition pockets around the active site seem to be formed upon binding of the 
inhibitor, which complicates the exploration of potential extra binding sites. 
   Several papers have mentioned the possible presence of an exosite on rhomboid proteases, first as a 
proposed model [33], and later supported by calculations [70] and experimental data [30, 71]. In addition, 
a ubiquitin interaction motif was found on the cytosolic domain of RHBDL4 [71]. These areas of the 
rhomboid protease could form extra interaction sites for inhibitors, and a combination of an active site 
binder with an exosite binder would likely provide higher selectivity and potency. However, such 
inhibitors will require additional structural information as well as considerable synthetic chemistry 
efforts. 
   Due to the roles of rhomboids in medically relevant processes, the future may bring validation of a 
rhomboid protease as a drug target. All reported inhibitors to date display a covalent inhibition 
mechanism. Although drug development programs tend to favor reversible inhibitors, recent years have 
seen an increase in attention for covalent binders [72, 73]. It is perhaps interesting to note that compounds 
with -lactam and -lactone scaffolds are currently applied in the treatment of several diseases, such as 
bacterial infections and obesity. Both scaffolds may therefore form suitable starting points for future 
development of rhomboid targeting drugs, if selectivity and potency requirements can be met.  Reversible 
inhibitors of rhomboid proteases have not yet been reported. One of the reasons may be the low affinity of 
rhomboids towards their substrates in comparison with other proteases [44]. As a consequence, the 
affinity towards substrate-inspired reversible inhibitors may also be low. Future efforts in high-throughput 
screening and structure-based design are required to confirm or contest this idea. 
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